Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension; and LIQ865, a sustained-release formulation of bupivacaine for the treatment of local post-operative pain. The company also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
IPO Year: 2018
Exchange: NASDAQ
Website: liquidia.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/20/2024 | $20.00 | Overweight | Wells Fargo |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 8/19/2024 | Outperform → Strong Buy | Raymond James | |
| 8/16/2024 | $27.00 | Outperform | Raymond James |
| 6/25/2024 | Perform | Oppenheimer | |
| 1/5/2024 | $18.00 → $28.00 | Buy | Needham |
| 9/19/2022 | $3.00 | Underperform | Wedbush |
| 9/1/2022 | $3.00 | Neutral → Underperform | Wedbush |
| 7/22/2022 | $15.00 | Buy | Ladenburg Thalmann |
| 5/31/2022 | $14.00 | Buy | BTIG Research |
4 - Liquidia Corp (0001819576) (Issuer)
4 - Liquidia Corp (0001819576) (Issuer)
4 - Liquidia Corp (0001819576) (Issuer)
4 - Liquidia Corp (0001819576) (Issuer)
4 - Liquidia Corp (0001819576) (Issuer)
4 - Liquidia Corp (0001819576) (Issuer)
4 - Liquidia Corp (0001819576) (Issuer)
4 - Liquidia Corp (0001819576) (Issuer)
4 - Liquidia Corp (0001819576) (Issuer)
4 - Liquidia Corp (0001819576) (Issuer)
MORRISVILLE, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for YUTREPIA™ (treprostinil) inhalation powder to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The FDA confirmed that the resubmission was a complete, Class 1 response to the previous action letter issued on August 16, 2024, which granted tentative approval of YUTREPIA for both PAH and PH-ILD. The F
- Data from the ASCENT study of LIQ861 (YUTREPIA™) in PH-ILD patients highlights safety, tolerability, exploratory changes in six-minute walk distance, cardiac effort and quality of life - Case study highlights the long-term safety and tolerability of LIQ861 (YUTREPIA) in a PAH patient transitioning from parenteral treprostinil in INSPIRE study MORRISVILLE, N.C., March 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced the company will present three posters at the American Thoracic Society (ATS) 2025 International Conference, taking p
Targeting final FDA approval of YUTREPIA™ after expiration of regulatory exclusivity on May 23, 2025Advancing pipeline of inhaled treprostinil products in clinical studiesStrengthened financial position by up to $100 million via amendment to existing financing agreement with HealthCare Royalty Partners (HCRx)Company to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., March 19, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today reported financial results for the full year ended December 31, 2024. The company will also host a webcast at 8:30 a.m. ET on March 19,
MORRISVILLE, N.C., March 18, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that it has entered into a sixth amendment to its agreement with HealthCare Royalty ("HCRx") to provide for up to an additional $100 million of financing in three tranches (the "Sixth Amendment"), subject to certain closing conditions including the funding conditions discussed below. Liquidia intends to use the proceeds to fund ongoing commercial development of YUTREPIA™ (treprostinil) inhalation powder for the potential treatment of pulmonary arterial hypertension (PAH) and pulm
MORRISVILLE, N.C., March 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its full year 2024 financial results on Wednesday, March 19, 2025. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The live webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location. About Liquidia CorporationLiquidia Corporatio
BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Arthur S. Kirsch to the Company's Board of Directors, effective immediately. Mr. Kirsch has decades of experience in investment banking and capital markets, as well as extensive knowledge of the healthcare and life sciences industries. Mr. Kirsch is currently a Senior Advisor with Alvarez & Marsal's Life Sciences Industry Group, and over the course of his 30-year career has held numerous roles in mergers and acqui
MORRISVILLE, N.C., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) announced today that Dr. Roger Jeffs, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, beginning at approximately 9:45 a.m. Pacific Time (12:45 p.m. Eastern Time) at the Westin St. Francis in San Francisco, California. Access to a live, audio-only webcast will be available on the "Investors" page of Liquidia's website at https://liquidia.com/investors/events-and-presentations. A replay and transcript of the webcast will be archived on the company's website for at least 30 days. About Liquidia CorporationLiquidia Corporation is a
Received tentative approval from the FDA for YUTREPIA™ (treprostinil) inhalation powder for both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)U.S. Supreme Court rejected final appeal of ‘793 patent decision, marking victories with respect to three patents originally asserted final and not subject to further appealStrengthened balance sheet by raising approximately $100 million in additional capital MORRISVILLE, N.C., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today reported financi
MORRISVILLE, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that the company will present at the Stifel 2024 Healthcare Conference in New York City on Tuesday, November 19, 2024, from 3:00 – 3:30 p.m. ET. Access to the live webcasts will be available to investors and other interested parties via Liquidia's website at https://liquidia.com/investors/events-and-presentations. An archived, recorded version of each presentation will be available on Liquidia's website for at least 30 days following the event. About Liquidia CorporationLiquidi
MORRISVILLE, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its third quarter 2024 financial results on Monday, November 11, 2024. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The live webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location. About Liquidia CorporationLiquidia Corpora
Submission status for Liquidia Technologies, Inc.'s drug YUTREPIA (ORIG-1) with active ingredient TREPROSTINIL has changed to 'Tentative Approval' on 11/04/2021. Application Category: NDA, Application Number: 213005, Application Classification: Type 3 - New Dosage Form
BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Arthur S. Kirsch to the Company's Board of Directors, effective immediately. Mr. Kirsch has decades of experience in investment banking and capital markets, as well as extensive knowledge of the healthcare and life sciences industries. Mr. Kirsch is currently a Senior Advisor with Alvarez & Marsal's Life Sciences Industry Group, and over the course of his 30-year career has held numerous roles in mergers and acqui
GAITHERSBURG, Md., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of Neal Fowler and Don DeGolyer to its Board of Directors effective October 1, 2023, with initial terms expiring at Emergent's 2024 Annual Meeting of Stockholders. Both joined as independent directors and bring more than 70 years of combined biopharmaceutical industry and sales experience. "Neal and Don bring unique and extensive expertise to Emergent as the company defines its future in this post-pandemic environment," said Emergent Chairman Dr. Zsolt Harsanyi, Ph.D. "Maintaining our focus on our mission of protecting and enhancing life, these industry veterans add v
MORRISVILLE, N.C., July 21, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) today announced that, in connection with the previously announced appointment of Rajeev Saggar, M.D., Liquidia's new Chief Medical Officer, it has agreed to grant him an employment inducement equity award. As previously disclosed in a Current Report on Form 8-K filed with the Securities and Exchange Commission on June 22, 2022 ("Form 8-K"), Liquidia has agreed to grant Dr. Saggar initial equity awards upon his commencement of employment, which includes a stock option exercisable for 200,000 shares of Liquidia's common stock under the Liquidia Corporation 2022 Inducement Plan (the "Inducement Plan"). The
MORRISVILLE, N.C., June 20, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) ("Liquidia" or the "Company") today announced the appointment of Rajeev Saggar, M.D., to the position of Chief Medical Officer. In this role, Dr. Saggar will oversee all aspects of research, clinical development, medical affairs, and regulatory affairs for Liquidia, assuming responsibilities on July 18, 2022. Roger Jeffs, Chief Executive Officer of Liquidia, said: "We are excited to add a leader of Dr. Saggar's caliber to our team as we prepare for the launch of YUTREPIA™ (treprostinil) inhalation powder upon receipt of final FDA approval. His expertise and credibility in treating patients across a wid
RESEARCH TRIANGLE PARK, N.C., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced Michael Kaseta has been appointed Chief Financial Officer (CFO), effective immediately. He succeeds Steve Bariahtaris who has served as Liquidia’s interim CFO since August 2020. Mr. Bariahtaris has agreed to provide assistance to the Company for a short period of time to support a smooth transition. “After an extensive search and thorough review of many outstanding candidates, it is with great pleasure that, today, we welcome Mike Kaseta to the Liquidia team,” said Neal Fowler, Chief Executive Officer at Liquidia. “I am confident that Mike’s financial expertise, business acu
EFFECT - Liquidia Corp (0001819576) (Filer)
S-3 - Liquidia Corp (0001819576) (Filer)
S-8 - Liquidia Corp (0001819576) (Filer)
S-8 - Liquidia Corp (0001819576) (Filer)
10-K - Liquidia Corp (0001819576) (Filer)
8-K - Liquidia Corp (0001819576) (Filer)
8-K - Liquidia Corp (0001819576) (Filer)
8-K - Liquidia Corp (0001819576) (Filer)
SCHEDULE 13G/A - Liquidia Corp (0001819576) (Subject)
8-K - Liquidia Corp (0001819576) (Filer)
Wells Fargo initiated coverage of Liquidia Technologies with a rating of Overweight and set a new price target of $20.00
Scotiabank initiated coverage of Liquidia Technologies with a rating of Sector Outperform
Raymond James upgraded Liquidia Technologies from Outperform to Strong Buy
Raymond James initiated coverage of Liquidia Technologies with a rating of Outperform and set a new price target of $27.00
Oppenheimer initiated coverage of Liquidia Technologies with a rating of Perform
Needham reiterated coverage of Liquidia Technologies with a rating of Buy and set a new price target of $28.00 from $18.00 previously
Wedbush resumed coverage of Liquidia Technologies with a rating of Underperform and set a new price target of $3.00
Wedbush downgraded Liquidia Technologies from Neutral to Underperform and set a new price target of $3.00
Ladenburg Thalmann initiated coverage of Liquidia Technologies with a rating of Buy and set a new price target of $15.00
BTIG Research initiated coverage of Liquidia Technologies with a rating of Buy and set a new price target of $14.00
4 - Liquidia Corp (0001819576) (Issuer)
4 - Liquidia Corp (0001819576) (Issuer)
4 - Liquidia Corp (0001819576) (Issuer)
4 - Liquidia Corp (0001819576) (Issuer)
4 - Liquidia Corp (0001819576) (Issuer)
MORRISVILLE, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its third quarter 2024 financial results on Monday, November 11, 2024. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The live webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location. About Liquidia CorporationLiquidia Corpora
MORRISVILLE, N.C., July 31, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its second quarter 2024 financial results on August 7, 2024. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. The live webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location.About Liquidia CorporationLiquidia Corporation is a bi
MORRISVILLE, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) announced today that it will report its first quarter 2024 financial results on May 14, 2024. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. The live webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location.About Liquidia CorporationLiquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and ot
MORRISVILLE, N.C., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) announced today that it will report its third quarter 2023 financial results on Tuesday, November 7, 2023. The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of 30 days at the same location. About Liquidia Corporation Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension
MORRISVILLE, N.C., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) announced today that it will report its second quarter 2023 financial results on Thursday, August 10, 2023. The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of 30 days at the same location. About Liquidia Corporation Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertensio
MORRISVILLE, N.C., April 27, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) announced today that it will report its first quarter 2023 financial results on Thursday, May 4, 2023. The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of 30 days at the same location. About Liquidia CorporationLiquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and
MORRISVILLE, N.C., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) ("Liquidia" or the "Company") today reported financial results for the third quarter ended September 30, 2022. The Company will host a webcast and conference call at 8:30 a.m. ET to discuss the third quarter 2022 financial results and provide a corporate update. Roger Jeffs, Liquidia's Chief Executive Officer, said: "The third quarter marked a critical juncture in our mission to provide YUTREPIA™ (treprostinil) inhalation powder to patients with PAH and PH-ILD. We have now demonstrated in at least one legal forum that each of the patent claims asserted against us is invalid or not infringed. We will co
MORRISVILLE, N.C., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) announced today that it will report its third quarter 2022 financial results on Tuesday, November 8, 2022. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. The live call may be accessed by dialing 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and entering the conference code: 7467713. A webcast of the call will be available and archived for 30 days on Liquidia's website at https://liquidia.com/index.php/investors/events-and-presentations. About Liquidia CorporationLiquidia Corporation is a biopharma
District Court ruling was favorable on ‘066 patent and unfavorable on ‘793 patentAll patent claims asserted have been found to be either invalid or not infringed by District Court or U.S. Patent Trial and Appeal Board (PTAB)PTAB decision to invalidate all claims of ‘793 patent is not affectedAbility to seek final FDA approval of YUTREPIA™ (treprostinil) inhalation powder is contingent on affirmation of the PTAB decision or reversal of District Court decision regarding the ‘793 patent MORRISVILLE, N.C., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) announced today that a ruling was issued by Judge Andrews, who is presiding over the litigation filed by United Therapeu
MORRISVILLE, N.C., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) announced today that it will report its second quarter 2022 financial results on Thursday, August 11, 2022. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. The live call may be accessed by dialing 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and entering the conference code: 8369322. A webcast of the call will be available and archived for 30 days on Liquidia's website at https://liquidia.com/index.php/investors/events-and-presentations. About Liquidia CorporationLiquidia Corporation is a biopharm
SC 13G/A - Liquidia Corp (0001819576) (Subject)
SC 13D/A - Liquidia Corp (0001819576) (Subject)
SC 13D/A - Liquidia Corp (0001819576) (Subject)
SC 13G/A - Liquidia Corp (0001819576) (Subject)
SC 13G/A - Liquidia Corp (0001819576) (Subject)
SC 13G - Liquidia Corp (0001819576) (Subject)
SC 13G - Liquidia Corp (0001819576) (Subject)
SC 13D/A - Liquidia Corp (0001819576) (Subject)
SC 13G - Liquidia Corp (0001819576) (Subject)
SC 13G/A - Liquidia Corp (0001819576) (Subject)